Drugs / NGFR-transduced Autologous T Lymphocytes
NGFR-transduced Autologous T Lymphocytes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01955460 | Oct 2014 → Oct 2027 expected | cutaneous melanoma, metastatic melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01740557 | Jan 2015 → Apr 2023 | cutaneous melanoma, metastatic melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGFR-transduced Autologous T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01740557 ↗ |
| Action | Deplete | “Adding these genes to the T cells may help them kill more tumor cells when they are put back in the body.” NCT01955460 ↗ |
| Modality | Cell therapy | “genetically modified therapeutic autologous lymphocytes (patient's own white blood cells)” NCT01740557 ↗ |
| Route | Intravenous | “Given IV” NCT01740557 ↗ |